| [1] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA: A Cancer J Clin, 2023, 73(1): 17-48.
|
| [2] |
Hills RD, Pontefract BA, Mishcon HR, et al. Gut microbiome: profound implications for diet and disease[J]. Nutrients, 2019, 11(7): 1613.
|
| [3] |
Jaye K, Li CG, Bhuyan DJ. The complex interplay of gut microbiota with the five most common cancer types: from carcinogenesis to therapeutics to prognoses[J]. Crit Rev Oncol Hematol, 2021, 165: 103429.
|
| [4] |
Scott AJ, Alexander JL, Merrifield CA, et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis[J]. Gut, 2019, 68(9): 1624-1632.
|
| [5] |
AAlizadehmohajer N, Shojaeifar S, Nedaeinia R, et al. Association between the microbiota and women’s cancers-cause or consequences？[J]. Biomed Pharmacother, 2020, 127: 110203.
|
| [6] |
Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing[J]. Nature, 2010, 464(7285): 59-65.
|
| [7] |
Yaghjyan L, Mai V, Darville LNF, et al. Associations of gut microbiome with endogenous estrogen levels in healthy postmenopausal women[J]. Cancer Causes Control, 2023, 34(10)：873-881.
|
| [8] |
Wang N, Yang J, Han W, et al. Identifying distinctive tissue and fecal microbial signatures and the tumor-promoting effects of deoxycholic acid on breast cancer[J]. Front Cell Infect Microbiol, 2022, 12: 1029905.
|
| [9] |
Byrd DA, Vogtmann E, Wu Z, et al. Associations of fecal microbial profiles with breast cancer and nonmalignant breast disease in the Ghana Breast Health Study[J]. Int J Cancer, 2021, 148(11): 2712-2723.
|
| [10] |
Gravena AAF, Romeiro Lopes TC, Demitto MO, et al. The obesity and the risk of breast cancer among pre and postmenopausal women[J]. Asian Pac J Cancer Prev, 2018, 19(9): 2429-2436.
|
| [11] |
Zengul AG, Demark-Wahnefried W, Barnes S, et al. Associations between dietary fiber, the fecal microbiota and estrogen metabolism in postmenopausal women with breast cancer[J]. Nutr Cancer, 2021, 73(7): 1108-1117.
|
| [12] |
Sampsell K, Hao D, Reimer RA. The gut microbiota: a potential gateway to improved health outcomes in breast cancer treatment and survivorship[J]. Int J Mol Sci, 2020, 21(23): 9239.
|
| [13] |
Goedecke JH, Tootla M, Keswell D. Ethnic differences in regional adipose tissue oestrogen receptor gene expression[J]. Endocr Connect, 2019, 8(1): 32-38.
|
| [14] |
Sampsell K, Hao D, Reimer R. The gut microbiota: a potential gateway to improved health outcomes in breast cancer treatment and survivorship[J]. Int J Mol Sci, 2020, 21(23): 9239.
|
| [15] |
Amoroso C, Perillo F, Strati F, et al. The role of gut microbiota biomodulators on mucosal immunity and intestinal inflammation[J]. Cells, 2020, 9(5): 1234.
|
| [16] |
Wells JM, Brummer RJ, Derrien M, et al. Homeostasis of the gut barrier and potential biomarkers[J]. Am J Physiol Gastrointest Liver Physiol, 2017, 312(3): G171-G193.
|
| [17] |
Rutkowski MR, Stephen TL, Svoronos N, et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation[J]. Cancer Cell, 2015, 27(1): 27-40.
|
| [18] |
Mantovani A, Ponzetta A, Inforzato A, et al. Innate immunity, inflammation and tumour progression: double-edged swords[J]. J Intern Med, 2019, 285(5): 524-532.
|
| [19] |
Goedert JJ, Hua X, Bilelecka A, et al. Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota[J]. Br J Cancer, 2018, 118(4): 471-479.
|
| [20] |
Yang Y, Li L, Xu C, et al. Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis[J]. Gut, 2020, 70(8): 1495-1506.
|
| [21] |
Wu J, Wang K, Wang X, et al. The role of the gut microbiome and its metabolites in metabolic diseases[J]. Protein Cell, 2021, 12(5): 360-373.
|
| [22] |
Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(6): 356-365.
|
| [23] |
Shi J, Geng C, Sang M, et al. Effect of gastrointestinal microbiome and its diversity on the expression of tumor-infiltrating lymphocytes in breast cancer[J]. Oncol Lett, 2019, 17(6): 5050-5056.
|
| [24] |
Banerjee S, Wei Z, Tan F, et al. Distinct microbiological signatures associated with triple negative breast cancer[J]. Sci Rep, 2015, 5(1): 15162.
|
| [25] |
Thompson KJ, Ingle JN, Tang X, et al. A comprehensive analysis of breast cancer microbiota and host gene expression[J]. PLoS One, 2017, 12(11): e0188873.
|
| [26] |
Parida S, Wu S, Siddharth S, et al. A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates notch and β-catenin axes[J]. Cancer Discov, 2021, 11(5): 1138-1157.
|
| [27] |
Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom intermediates[J]. Nat Rev Microbiol, 2021, 19(2): 77-94.
|
| [28] |
Toumazi D, El Daccache S, Constantinou C. An unexpected link: the role of mammary and gut microbiota on breast cancer development and management (review)[J]. Oncol Rep, 2021, 45(5): 80.
|
| [29] |
Luu TH, Bard JM, Carbonnelle D, et al. Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells[J]. Cell Oncol (Dordr), 2018, 41(1): 13-24.
|
| [30] |
Kovács P, Csonka T, Kovács T, et al. Lithocholic acid, a metabolite of the microbiome, increases oxidative stress in breast cancer[J]. Cancers (Basel), 2019, 11(9): 1255.
|
| [31] |
Zhu J, Liao M, Yao Z, et al. Breast cancer in postmenopausal women is associated with an altered gut metagenome[J]. Microbiome, 2018, 6(1): 136.
|
| [32] |
Yadav M, Verma MK, Chauhan NS. A review of metabolic potential of human gut microbiome in human nutrition[J]. Arch Microbiol, 2018, 200(2): 203-217.
|
| [33] |
Devoy C, Flores BY, Tangney M. Understanding and harnessing triple negative breast cancer-related microbiota in oncology[J]. Front Oncol, 2022, 12: 1 020 121.
|
| [34] |
Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies[J]. Microbiome, 2018, 6(1): 92.
|
| [35] |
Rupert B. Trastuzumab-deruxtecan：an investigational agent for the treatment of HER2-positive breast cancer[J]. Expert Opin Investig Drugs, 2020, 29(9): 901-910.
|
| [36] |
Di Modica M, Gargari G, Regondi V, et al. Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-Positive breast cancer[J]. Cancer Res, 2021, 81(8): 2195-2206.
|
| [37] |
Mikó E, Kovács T, Sebő É，et al. Microbiome-microbial metabolome-cancer cell interactions in breast cancer-familiar, but unexplored[J]. Cells, 2019, 8(4): 293.
|
| [38] |
Mamgain G, Patra P, Naithani M, et al. The role of microbiota in the development of cancer tumour cells and lymphoma of B and T cells[J]. Cureus, 2021, 13(10): e19047.
|
| [39] |
Liu T, Wu Y, Wang L, et al. A more robust gut microbiota in calorie-restricted mice is associated with attenuated intestinal injury caused by the chemotherapy drug cyclophosphamide[J]. mBio, 2019, 10(2): e02903-e02918.
|
| [40] |
Kurozumi S, Fujii T, Matsumoto H, et al. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer[J]. Med Mol Morphol, 2017, 50(4): 185-194.
|
| [41] |
Schmid P, Adams S, Rugo HS, et al. IMpassion130 trial investigators. atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22): 2108-2121.
|
| [42] |
Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371): 97-103.
|
| [43] |
Jin Y, Dong H, Xia L, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC[J]. J Thorac Oncol, 2019, 14(8): 1378-1389.
|
| [44] |
Mao J, Wang D, Long J, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers[J]. J Immunother Cancer, 2021, 9(12): e003334.
|
| [45] |
Kiousi DE, Kouroutzidou AZ, Neanidis K, et al. The role of the gut microbiome in cancer immunotherapy: current knowledge and future directions[J]. Cancers (Basel), 2023, 15(7): 2101.
|
| [46] |
Chen D, Jin D, Huang S, et al. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota[J]. Cancer Lett, 2020, 469: 456-467.
|
| [47] |
Gerassy-Vainberg S, Blatt A, Danin-Poleg Y, et al. Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction[J]. Gut, 2018, 67(1): 97-107.
|